BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 7627972)

  • 1. Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models.
    Watson SA; Morris TM; Robinson G; Crimmin MJ; Brown PD; Hardcastle JD
    Cancer Res; 1995 Aug; 55(16):3629-33. PubMed ID: 7627972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined treatment with serine protease inhibitor aprotinin and matrix metalloproteinase inhibitor Batimastat (BB-94) does not prevent invasion of human esophageal and ovarian carcinoma cells in vivo.
    Della Porta P; Soeltl R; Krell HW; Collins K; O'Donoghue M; Schmitt M; Krüger A
    Anticancer Res; 1999; 19(5B):3809-16. PubMed ID: 10628317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The matrix metalloproteinase inhibitor batimastat (BB-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice.
    Low JA; Johnson MD; Bone EA; Dickson RB
    Clin Cancer Res; 1996 Jul; 2(7):1207-14. PubMed ID: 9816289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice.
    Wang X; Fu X; Brown PD; Crimmin MJ; Hoffman RM
    Cancer Res; 1994 Sep; 54(17):4726-8. PubMed ID: 8062271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of matrix metalloproteinase inhibitor BB-94 on liver cancer growth and metastasis in a patient-like orthotopic model LCI-D20.
    Bu W; Tang ZY; Sun FX; Ye SL; Liu KD; Xue Q; Chen J; Gao DM
    Hepatogastroenterology; 1998; 45(22):1056-61. PubMed ID: 9756006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts.
    Giavazzi R; Garofalo A; Ferri C; Lucchini V; Bone EA; Chiari S; Brown PD; Nicoletti MI; Taraboletti G
    Clin Cancer Res; 1998 Apr; 4(4):985-92. PubMed ID: 9563894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94).
    Eccles SA; Box GM; Court WJ; Bone EA; Thomas W; Brown PD
    Cancer Res; 1996 Jun; 56(12):2815-22. PubMed ID: 8665519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts.
    Davies B; Brown PD; East N; Crimmin MJ; Balkwill FR
    Cancer Res; 1993 May; 53(9):2087-91. PubMed ID: 8347186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matrix metalloproteinase inhibition attenuates human pancreatic cancer growth in vitro and decreases mortality and tumorigenesis in vivo.
    Zervos EE; Norman JG; Gower WR; Franz MG; Rosemurgy AS
    J Surg Res; 1997 May; 69(2):367-71. PubMed ID: 9224409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [An experimental study of matrix metalloproteinase inhibitor BB-94 inhibits the invasion and metastasis of the human salivary adenoid cystic carcinoma in vitro and in vivo].
    Mao L; Yu S; Sun K
    Zhonghua Kou Qiang Yi Xue Za Zhi; 2001 Jul; 36(4):304-7. PubMed ID: 11718018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matrix metalloproteinase (MMP) inhibition selectively decreases type II MMP activity in a murine model of pancreatic cancer.
    Zervos EE; Shafii AE; Rosemurgy AS
    J Surg Res; 1999 Jan; 81(1):65-8. PubMed ID: 9889060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models.
    Lozonschi L; Sunamura M; Kobari M; Egawa S; Ding L; Matsuno S
    Cancer Res; 1999 Mar; 59(6):1252-8. PubMed ID: 10096556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice.
    Sledge GW; Qulali M; Goulet R; Bone EA; Fife R
    J Natl Cancer Inst; 1995 Oct; 87(20):1546-50. PubMed ID: 7563189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Matrix metalloproteinase inhibition prevents colon cancer peritoneal carcinomatosis development and prolongs survival in rats.
    Aparicio T; Kermorgant S; Dessirier V; Lewin MJ; Lehy T
    Carcinogenesis; 1999 Aug; 20(8):1445-51. PubMed ID: 10426790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of distant pulmonary metastasis of MDA-MB 435 human breast carcinoma established in mammary fat pads of nude mice by retroviral-mediated TIMP-2 gene transfer.
    Lee YK; So IS; Lee SC; Lee JH; Lee CW; Kim WM; Park MK; Lee ST; Park DY; Shin DY; Park CU; Kim YS
    J Gene Med; 2005 Feb; 7(2):145-57. PubMed ID: 15546163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of human breast cancer metastasis in nude mice by synthetic glycoamines.
    Glinsky GV; Price JE; Glinsky VV; Mossine VV; Kiriakova G; Metcalf JB
    Cancer Res; 1996 Dec; 56(23):5319-24. PubMed ID: 8968076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis.
    Krüger A; Soeltl R; Sopov I; Kopitz C; Arlt M; Magdolen V; Harbeck N; Gänsbacher B; Schmitt M
    Cancer Res; 2001 Feb; 61(4):1272-5. PubMed ID: 11245418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases.
    Taraboletti G; Garofalo A; Belotti D; Drudis T; Borsotti P; Scanziani E; Brown PD; Giavazzi R
    J Natl Cancer Inst; 1995 Feb; 87(4):293-8. PubMed ID: 7535861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel, orally administered nucleoside analogue, OGT 719, inhibits the liver invasive growth of a human colorectal tumor, C170HM2.
    Rohlff C; Watson SA; Morris TM; Skelton L; Jackman AL; Page MJ
    Cancer Res; 1999 Mar; 59(6):1268-72. PubMed ID: 10096558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production.
    Sweeney P; Karashima T; Kim SJ; Kedar D; Mian B; Huang S; Baker C; Fan Z; Hicklin DJ; Pettaway CA; Dinney CP
    Clin Cancer Res; 2002 Aug; 8(8):2714-24. PubMed ID: 12171905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.